| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | LB2501 relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) | Phase 1 | — | Biologics | Oncology | ||
Phase 1 data readout example | LB2501 relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) | Phase 1 | — | Biologics | Oncology | ||
Phase 1 data readout example | LB2501 relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) | Phase 1 | — | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Legend Biotech Corporation$31.52
-0.71 (-2.18%)
C 44Pipeline Score Overvalued Pharma · Clinical
Market Cap
5.46 B
EPS
-1.36
P/E Ratio
-
Value Trade
144.62 M
4.45 %
Week
15.9 %
1 Month
60.23 %
3 Month
6.49 %
6 Month
-27.18 %
5 Year
-20.62 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
3.20 M
52 Week Range
16.24 - 45.30
% held by Insiders
5.13 %
% held by Institutions
48.43 %
Enterprise Value
5.01 B
Total Shares
185.74 M
Short %
8.19 %
Float Shares
176.21 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C44
Pipeline Score $2.1B
Pipeline ValueOvervalued
Valuation Signal14
Drugs Scored0.4x
rNPV / MCap Top 60%
Small Cap (rank 363 of 905)
Percentile RankLegend Biotech Corporation carries a moderate pipeline score (44/100), with $3.5B risk-adjusted pipeline value, led by LUCAR-DKS1 NK cells in Relapsed/Refractory Autoimmune Diseases (Phase 1), across $58B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LUCAR-DKS1 NK cells Monoclonal antibody | Relapsed/Refractory Autoimmune Diseases | Phase 1 | NCT07095075 | 35% | $684M | RECRUITING | 36 | STALLED | D (30) | Dec 31, 2029 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) | relapsed and refractory multiple myeloma | Phase 3 | 2025-08-12 | |||
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) | relapsed and refractory multiple myeloma | Phase 3 | 2025-08-12 | |||
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) | relapsed and refractory multiple myeloma | Phase 3 | 2025-08-12 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LEGN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
LEGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LEGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LEGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LEGN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
LEGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Legend Biotech Corporation (LEGN) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How LEGN ranks across every disease it competes in| Indication | Rank | Phase | Best Drug | Top 3 Competitors | Market $B | LoA | Position |
|---|---|---|---|---|---|---|---|
| Esophageal Cancer | #21 of 39 | LB1908 | MRK AZN ONC | $1.85B | 0.89 | ||
| Gastric Cancer | #28 of 49 | LB1908 | AZN ONC JAZZ | $6.74B | 0.89 | ||
| Systemic Lupus Erythematosus | #31 of 32 | LUCAR-G79D T cells | BIIB VTRS BMY | $2.78B | 0 | ||
| Pancreatic Cancer | #36 of 73 | LB1908 | RVMD RCUS AZN | $3.7B | 0.89 | ||
| Lung Cancer | #51 of 79 | LB2102 | MRK GILD AMGN | $28.1B | 0.88 |